Jie Yuan

Dr. Jie Yuan

Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2015 in Marine Drugs
Verified
Journal Article
Open access
PDF file
YHYiwen Hu
Yiwen Hu
JCJiahui Chen
Jiahui Chen
HGHu Guping
Hu Guping
JYJianchen Yu
Jianchen Yu
XZXun Zhu
Xun Zhu
JYJie Yuan
Jie Yuan
Every year, hundreds of new compounds are discovered from the metabolites of marine organisms. Finding new and useful compounds is one of the crucial drivers for this field of research. Here we describe the statistics of bioactive compounds discovered from marine organisms from 1985 to 2012. This work is based on our database, which contains information on more than 15,000 chemical substances including 4196 bioactive marine natural products. We performed a comprehensive statistical analysis to understand the characteristics of the novel bioactive compounds and detail temporal trends, chemical structures, species distribution, and research progress. We hope this meta-analysis will provide useful information for research into the bioactivity of marine natural products and drug development.

29 March 2011 in Marine Drugs
Verified
Journal Article
Open access
PDF file
HGHu Guping
Hu Guping
JYJie Yuan
Jie Yuan
LSLi Sun
Li Sun
ZSZhigang She
Zhigang She
JWJue-Heng Wu
Jue-Heng Wu
SCSheng-Ping Chen
Sheng-Ping Chen
Since the 1960s, more than 20,000 compounds were discovered from marine organisms. In this paper we performed a quantitative analysis for the novel marine natural products reported between 1985 and 2008. The data was extracted mainly from the reviews of Faulkner and Blunt [1–26]. The organisms producing these marine natural products are divided into three major biological classes: marine microorganisms (including phytoplankton), marine algae and marine invertebrate. The marine natural products are divided into seven classes based on their chemical structure: terpenoids, steroids (including steroidal saponins), alkaloids, ethers (including ketals), phenols (including quinones), strigolactones, and peptides. The distribution and the temporal trend of these classes (biological classes and chemical structure classes) were investigated. We hope this article provides a comprehensive perspective on the research of marine natural products.

9 February 2010 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
GXGui'E Xie
Gui'E Xie
XZXun Zhu
Xun Zhu
QLQing Li
Qing Li
MGMinghui Gu
Minghui Gu
ZHZhenjian He
Zhenjian He
JYJie Yuan
Jie Yuan
Background and purpose:  The aims of this study were to investigate the anti‐cancer activity of SZ‐685C, an anthracycline analogue isolated from marine‐derived mangrove endophytic fungi, and to explore the molecular mechanisms underlying such activity.Experimental approach:  The effect of SZ‐685C on the viability of cancer cell lines was investigated using the 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl tetrazolium bromide (MTT) assay. SZ‐685C‐induced apoptosis was assessed by Annexin V‐fluorescein isothiocyanate/propidium iodide staining, terminal deoxynucleotidyl transferase‐mediated dUTP nick end labelling assay and analysis of caspase activation. The effect of SZ‐685C on the Akt/FOXO pathway was studied using Western blotting analysis, and the in vivo anti‐tumour efficacy was examined in an MDA‐MB‐435 breast cancer xenograft model.Key results:  SZ‐685C suppressed the proliferation of six cancer cell lines derived from human breast cancer, prostate cancer, glioma and hepatoma (IC50 values ranged from 3.0 to 9.6 µM) and the growth of breast cancer xenografts in mice. SZ‐685C had a direct apoptosis‐inducing effect through both the extrinsic and intrinsic apoptotic pathways, as shown by activation of caspase‐8 and 9 as well as effector caspase‐3 and poly (ADP‐ribose) polymerase. Phosphorylation of Akt and its downstream effectors, forkhead box protein O1 and forkhead box protein O3a, was down‐regulated in SZ‐685C‐treated cancer cells. Furthermore, the pro‐apoptotic protein Bim was up‐regulated by SZ‐685C treatment consistent with FOXO dephosphorylation.Conclusions and implications:  SZ‐685C could induce apoptosis through the Akt/FOXO pathway, which consequently leads to the observed anti‐tumour effect both in vitro and in vivo. Our data suggest that SZ‐685C may be a potentially promising Akt inhibitor and anti‐cancer drug candidate.

23 October 2013 in Cancers
Verified
Journal Article
Open access
PDF file
MLMengfeng Li
Mengfeng Li
Jun LiJun Li
Jun Li
LLLei Liu
Lei Liu
WLWei Li
Wei Li
YYYi Yang
Yi Yang
JYJie Yuan
Jie Yuan
Glioma represents a serious health problem worldwide. Despite advances in surgery, radiotherapy, chemotherapy, and targeting therapy, the disease remains one of the most lethal malignancies in humans, and new approaches to improvement of the efficacy of anti-glioma treatments are urgently needed. Thus, new therapeutic targets and tools should be developed based on a better understanding of the molecular pathogenesis of glioma. In this context, microRNAs (miRNAs), a class of small, non-coding RNAs, play a pivotal role in the development of the malignant phenotype of glioma cells, including cell survival, proliferation, differentiation, tumor angiogenesis, and stem cell generation. This review will discuss the biological functions of miRNAs in human glioma and their implications in improving clinical diagnosis, prediction of prognosis, and anti-glioma therapy.

23 March 2012 in Marine Drugs
Verified
Journal Article
Open access
PDF file
XZXun Zhu
Xun Zhu
ZHZhenjian He
Zhenjian He
JWJueheng Wu
Jueheng Wu
JYJie Yuan
Jie Yuan
WWWeitao Wen
Weitao Wen
MLMengfeng Li
Mengfeng Li
Breast cancer remains a major health problem worldwide. While chemotherapy represents an important therapeutic modality against breast cancer, limitations in the clinical use of chemotherapy remain formidable because of chemoresistance. The HER2/PI-3K/Akt pathway has been demonstrated to play a causal role in conferring a broad chemoresistance in breast cancer cells and thus justified to be a target for enhancing the effects of anti-breast cancer chemotherapies, such as adriamycin (ADR). Agents that can either enhance the effects of chemotherapeutics or overcome chemoresistance are urgently needed for the treatment of breast cancer. In this context, SZ-685C, an agent that has been previously shown, as such, to suppress Akt signaling, is expected to increase the efficacy of chemotherapy. Our current study investigated whether SZ-685C can override chemoresistance through inhibiting Akt signaling in human breast cancer cells. ADR-resistant cells derived from human breast cancer cell lines MCF-7, MCF-7/ADR and MCF-7/Akt, were used as models to test the effects of SZ-685C. We found that SZ-685C suppressed the Akt pathway and induced apoptosis in MCF-7/ADR and MCF-7/Akt cells that are resistant to ADR treatment, leading to antitumor effects both in vitro and in vivo. Our data suggest that use of SZ-685C might represent a potentially promising approach to the treatment of ADR-resistant breast cancer.

11 December 2013 in Marine Drugs
Verified
Journal Article
Open access
PDF file
BDBo Ding
Bo Ding
JYJie Yuan
Jie Yuan
XHXishan Huang
Xishan Huang
WWWeitao Wen
Weitao Wen
XZXun Zhu
Xun Zhu
ZSZhigang She
Zhigang She
Three new phomoxanthone compounds, phomolactonexanthones A (1), B (2) and deacetylphomoxanthone C (3), along with five known phomoxanthones, including dicerandrol A (4), dicerandrol B (5), dicerandrol (6), deacetylphomoxanthone B (7) and penexanthone A (8), were isolated in the metabolites of the fungus Phomopsis sp. HNY29-2B, which was isolated from the mangrove plants. The structures of compounds 1–3 were established on the basis of spectroscopic analysis. All compounds were evaluated against four human cancer cell lines including human breast MDA-MB-435, human colon HCT-116, human lung Calu-3 and human liver Huh7 by MTT assay. The compounds 4, 5, 7 and 8 showed cyctotoxic activities against tested cancer cell lines (IC50 < 10 μM).